肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

关于乳腺癌，你应该知道的知识

2016-04-18 @全国卫生12320 新浪微博

乳腺癌肿瘤防治
关注








版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=166282, encodeId=85361662827a, content=恩，归纳的很好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Wed Dec 28 09:28:05 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139411, encodeId=1c5c139411e8, content=深度好文，值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:39:11 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83638, encodeId=c29283638dc, content=学了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Wed May 04 06:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79414, encodeId=6c14e9414ee, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79415, encodeId=2c08e9415e2, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79359, encodeId=fa10e93597f, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Apr 18 15:56:00 CST 2016, time=2016-04-18, status=1, ipAttribution=)]
    2016-12-28 ys2323

    恩，归纳的很好！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=166282, encodeId=85361662827a, content=恩，归纳的很好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Wed Dec 28 09:28:05 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139411, encodeId=1c5c139411e8, content=深度好文，值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:39:11 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83638, encodeId=c29283638dc, content=学了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Wed May 04 06:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79414, encodeId=6c14e9414ee, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79415, encodeId=2c08e9415e2, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79359, encodeId=fa10e93597f, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Apr 18 15:56:00 CST 2016, time=2016-04-18, status=1, ipAttribution=)]
    2016-10-03 1e10c84am36(暂无匿称)

    深度好文，值得关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=166282, encodeId=85361662827a, content=恩，归纳的很好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Wed Dec 28 09:28:05 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139411, encodeId=1c5c139411e8, content=深度好文，值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:39:11 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83638, encodeId=c29283638dc, content=学了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Wed May 04 06:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79414, encodeId=6c14e9414ee, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79415, encodeId=2c08e9415e2, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79359, encodeId=fa10e93597f, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Apr 18 15:56:00 CST 2016, time=2016-04-18, status=1, ipAttribution=)]
    2016-05-04 1de833cem82(暂无匿称)

    学了！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=166282, encodeId=85361662827a, content=恩，归纳的很好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Wed Dec 28 09:28:05 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139411, encodeId=1c5c139411e8, content=深度好文，值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:39:11 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83638, encodeId=c29283638dc, content=学了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Wed May 04 06:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79414, encodeId=6c14e9414ee, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79415, encodeId=2c08e9415e2, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79359, encodeId=fa10e93597f, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Apr 18 15:56:00 CST 2016, time=2016-04-18, status=1, ipAttribution=)]
    2016-04-19 李继凯

    文章不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=166282, encodeId=85361662827a, content=恩，归纳的很好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Wed Dec 28 09:28:05 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139411, encodeId=1c5c139411e8, content=深度好文，值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:39:11 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83638, encodeId=c29283638dc, content=学了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Wed May 04 06:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79414, encodeId=6c14e9414ee, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79415, encodeId=2c08e9415e2, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79359, encodeId=fa10e93597f, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Apr 18 15:56:00 CST 2016, time=2016-04-18, status=1, ipAttribution=)]
    2016-04-19 李继凯

    值得关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=166282, encodeId=85361662827a, content=恩，归纳的很好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Wed Dec 28 09:28:05 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139411, encodeId=1c5c139411e8, content=深度好文，值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:39:11 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83638, encodeId=c29283638dc, content=学了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Wed May 04 06:43:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79414, encodeId=6c14e9414ee, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79415, encodeId=2c08e9415e2, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 00:45:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79359, encodeId=fa10e93597f, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Apr 18 15:56:00 CST 2016, time=2016-04-18, status=1, ipAttribution=)]
    2016-04-18 dhzzm

    学习了，很好

    0

相关资讯

AACR 2016：低脂肪饮食有助于绝经后女性避免致命性乳腺癌

根据在临床试验全体会议的一项研究，在美国癌症研究协会（AACR）年度会议发表的题为“乳腺癌转化临床试验”结果表明，与那些没有遵循饮食方案的女性相比，那些消耗低脂肪饮食的女性对于死于浸润性乳腺癌降的风险大约减少8年，生存率也有所提高。在近一个半世纪以前，膳食脂肪摄入量与乳腺癌预后之间的关联就被讨论过，但观察结果尚无定论。为了确定低脂肪膳食模式对乳腺癌的影响，洛杉矶生物医学研究所的医学博士Rowan

NCCN：关注癌症幸存者的性功能障碍

性功能障碍是癌症幸存者常见的问题，并且可能一直是个重要的生存问题，直到出现基于证据的干预治疗，这才真正的帮助到了男性和女性，在第21次美国国家综合癌症网络年会上的专家指出。

Ann Surg：越来越多的乳腺癌患者选择对侧预防性乳房切除术，但对长期生存并没有用

近期发表在Ann Surg的研究称，过去十年时间里，进行对侧预防性乳房切除术的乳腺浸润性癌患者翻了3倍，但是与保乳术患者相比，目前并没有预防性切除乳房的生存益处。布莱根妇女医院和丹那法伯/布莱根妇女癌症中心国际肿瘤学项目主任Mehra Golshan和同事对SEER数据库中1998-2012年的496,488名单侧Ⅰ -Ⅲ期乳腺癌患者进行了研究。数据显示，59.6%的患者进行了保乳术(BCS)，3

Oncogene：上海生科院等揭示miR-155在乳腺癌发生发展中的新功能

国际学术期刊Oncogene 于4月11日在线发表了中国科学院上海生命科学研究院生物化学与细胞生物学研究所刘默芳研究组关于miR-155调控ErbB2-介导的乳腺上皮细胞恶性转化的最新研究成果，揭示了miR-155在乳腺癌发生发展中的一种新功能和作用机制。ErbB2是乳腺癌的一个重要致癌基因，约在50%非侵袭性乳腺癌、25%的浸润性乳腺癌中高表达，在乳腺癌发生发展中具有重要功能。针对ErbB2高表

Nat Commun：研究发现乳腺癌的肿瘤生长依赖于脂肪的供应量

  NatureCommunications发表的一篇论文报道乳腺癌细胞需要从胞外环境中吸收脂肪来满足继续增值的需求，参与该过程的一个重要蛋白叫LIPG，它是细胞膜表面的一种酶，缺乏该酶时，肿瘤细胞的生长会被抑制。500多例不同类型的乳腺癌患者临床样本分析结果显示，超过85%的患者LIPG蛋白水平显著提高。 在西班牙，乳腺癌患者在女性癌症患者中排名第一，在全国癌症患者中排名第四（数

JAMA Oncol：来那替尼联合紫杉醇治疗乳腺癌可减少中枢神经系统转移频率

虽然来那替尼联合紫杉醇并不优于曲妥珠单抗加紫杉酚作为ERBB2阳性转移性乳腺癌无进展生存期的一线治疗方法，但根据JAMA Oncology在线发表的一篇文章，这种联合治疗方法可以延迟发作和降低发生中枢神经系统转移瘤的频率，这一发现需要更大的研究来证实。大多数转移性ERBB2阳性乳腺癌患者会特定发展为肝转移，约半数患者有中枢神经系统受累的不良预后。布鲁塞尔朱尔茨博尔代研究所的医学博士Ahmad Aw